Literature DB >> 33103432

Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?

Yibin Xu1, Ding Xue1, Armand Bankhead2,3, Nouri Neamati1.   

Abstract

Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy and targeted therapies. Suppressing the OXPHOS function might also influence the tumor microenvironment by alleviating hypoxia and improving the antitumor immune response. Thus, targeting OXPHOS is a promising strategy to treat various cancers. A growing arsenal of therapeutic agents is under development to inhibit this biological process. This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OXPHOS as drug targets. We also focus on the current development status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical applications.

Entities:  

Mesh:

Year:  2020        PMID: 33103432      PMCID: PMC9298160          DOI: 10.1021/acs.jmedchem.0c01013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  265 in total

1.  Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I.

Authors:  Volker Zickermann; Christophe Wirth; Hamid Nasiri; Karin Siegmund; Harald Schwalbe; Carola Hunte; Ulrich Brandt
Journal:  Science       Date:  2015-01-02       Impact factor: 47.728

2.  Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease.

Authors:  Gary D Glick; Rodrigue Rossignol; Costas A Lyssiotis; Daniel Wahl; Charles Lesch; Brian Sanchez; Xikui Liu; Ling-Yang Hao; Clarke Taylor; Alexander Hurd; James L M Ferrara; Victor Tkachev; Craig A Byersdorfer; Laszlo Boros; Anthony W Opipari
Journal:  J Pharmacol Exp Ther       Date:  2014-08-14       Impact factor: 4.030

3.  Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

Authors:  Joji Nagasawa; Atsushi Mizokami; Kiyoshi Koshida; Sei Yoshida; Kenichiro Naito; Mikio Namiki
Journal:  Int J Urol       Date:  2006-05       Impact factor: 3.369

4.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Authors:  Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

5.  Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.

Authors:  Michael D Aleo; Yi Luo; Rachel Swiss; Paul D Bonin; David M Potter; Yvonne Will
Journal:  Hepatology       Date:  2014-07-14       Impact factor: 17.425

6.  Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice.

Authors:  Ying Yan; Yian Wang; Qing Tan; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

7.  Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Authors:  Francesca Alvarez-Calderon; Mark A Gregory; Catherine Pham-Danis; Deborah DeRyckere; Brett M Stevens; Vadym Zaberezhnyy; Amanda A Hill; Lelisa Gemta; Amit Kumar; Vijay Kumar; Michael F Wempe; Daniel A Pollyea; Craig T Jordan; Natalie J Serkova; Douglas K Graham; James DeGregori
Journal:  Clin Cancer Res       Date:  2014-12-29       Impact factor: 12.531

8.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

9.  Cryo-EM structure of respiratory complex I at work.

Authors:  Kristian Parey; Ulrich Brandt; Hao Xie; Deryck J Mills; Karin Siegmund; Janet Vonck; Werner Kühlbrandt; Volker Zickermann
Journal:  Elife       Date:  2018-10-02       Impact factor: 8.140

10.  Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.

Authors:  Richa Bajpai; Aditi Sharma; Abhinav Achreja; Claudia L Edgar; Changyong Wei; Arusha A Siddiqa; Vikas A Gupta; Shannon M Matulis; Samuel K McBrayer; Anjali Mittal; Manali Rupji; Benjamin G Barwick; Sagar Lonial; Ajay K Nooka; Lawrence H Boise; Deepak Nagrath; Mala Shanmugam
Journal:  Nat Commun       Date:  2020-03-06       Impact factor: 14.919

View more
  12 in total

1.  Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer.

Authors:  Ding Xue; Yibin Xu; Armita Kyani; Joyeeta Roy; Lipeng Dai; Duxin Sun; Nouri Neamati
Journal:  J Med Chem       Date:  2022-02-15       Impact factor: 8.039

2.  Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.

Authors:  Ding Xue; Yibin Xu; Armita Kyani; Joyeeta Roy; Lipeng Dai; Duxin Sun; Nouri Neamati
Journal:  J Med Chem       Date:  2022-01-04       Impact factor: 8.039

3.  Glycyrrhetinic acid restricts mitochondrial energy metabolism by targeting SHMT2.

Authors:  Xiuxiu Jin; Li Li; Qinlu Peng; Chunmei Gan; Li Gao; Siyu He; Shuangyan Tan; Wenchen Pu; Yu Liu; Yanqiu Gong; Yuqin Yao; Gang Wang; Xiaohui Liu; Meng Gong; Peng Lei; Huiyuan Zhang; Shiqian Qi; Heng Xu; Hongbo Hu; Biao Dong; Yong Peng; Dan Su; Lunzhi Dai
Journal:  iScience       Date:  2022-05-04

4.  Development of antitumor biguanides targeting energy metabolism and stress responses in the tumor microenvironment.

Authors:  Takayuki Sakai; Yoshiyuki Matsuo; Kensuke Okuda; Kiichi Hirota; Mieko Tsuji; Tasuku Hirayama; Hideko Nagasawa
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

Review 5.  Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.

Authors:  Balaraman Kalyanaraman
Journal:  FASEB J       Date:  2022-04       Impact factor: 5.834

6.  Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers.

Authors:  Lingshuang Sheng; Di Fu; Yiwen Cao; Yujia Huo; Shuo Wang; Rong Shen; Pengpeng Xu; Shu Cheng; Li Wang; Weili Zhao
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

7.  Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.

Authors:  Benjamin J Reisman; Hui Guo; Haley E Ramsey; Madison T Wright; Bradley I Reinfeld; P Brent Ferrell; Gary A Sulikowski; W Kimryn Rathmell; Michael R Savona; Lars Plate; John L Rubinstein; Brian O Bachmann
Journal:  Nat Chem Biol       Date:  2021-12-02       Impact factor: 16.174

8.  Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.

Authors:  Jinhui Liu; Tian Chen; Min Yang; Zihang Zhong; Senmiao Ni; Sheng Yang; Fang Shao; Lixin Cai; Jianling Bai; Hao Yu
Journal:  Front Cell Dev Biol       Date:  2021-11-25

9.  Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.

Authors:  Emily M J Fennell; Lucas J Aponte-Collazo; Joshua D Wynn; Kristina Drizyte-Miller; Elisa Leung; Yoshimi Endo Greer; Paul R Graves; Andrew A Iwanowicz; Hani Ashamalla; Ekhson Holmuhamedov; Henk Lang; Donald S Karanewsky; Channing J Der; Walid A Houry; Stanley Lipkowitz; Edwin J Iwanowicz; Lee M Graves
Journal:  Pharmacol Res Perspect       Date:  2022-08

10.  Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects.

Authors:  Gang Cheng; Micael Hardy; Paytsar Topchyan; Ryan Zander; Peter Volberding; Weiguo Cui; Balaraman Kalyanaraman
Journal:  iScience       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.